Last reviewed · How we verify
Incretin analogues
Incretin analogues mimic the action of incretin hormones to stimulate insulin secretion in response to glucose intake, thereby lowering blood glucose levels in patients with type 2 diabetes.
Incretin analogues mimic the action of incretin hormones to stimulate insulin secretion in response to glucose intake, thereby lowering blood glucose levels in patients with type 2 diabetes. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Incretin analogues |
|---|---|
| Also known as | Liraglutide |
| Sponsor | Khoo Teck Puat Hospital |
| Drug class | Incretin mimetic (GLP-1 receptor agonist or GIP receptor agonist) |
| Target | GLP-1R or GIPR |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Incretin analogues are synthetic versions of glucagon-like peptide-1 (GLP-1) or glucose-dependent insulinotropic polypeptide (GIP) that enhance the body's natural incretin effect. These agents bind to incretin receptors on pancreatic beta cells, triggering glucose-dependent insulin secretion while simultaneously suppressing glucagon release. This mechanism is particularly effective postprandially and carries a lower hypoglycemia risk compared to insulin secretagogues.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Headache
- Hypoglycemia
Key clinical trials
- Glycemia in Diabetic Elders Trial (PHASE4)
- Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment (PHASE4)
- Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia (PHASE1)
- The Efficacy of Bariatric Surgery Compared to Medical Therapy in Controlling Type2 Diabetes Mellitus in Patients With Non Morbid Obesity. (PHASE2, PHASE3)
- Incretin and KATP Channels (NA)
- Incretin-based Drugs and Acute Pancreatitis
- Incretin-based Drugs and the Risk of Heart Failure
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Incretin analogues CI brief — competitive landscape report
- Incretin analogues updates RSS · CI watch RSS
- Khoo Teck Puat Hospital portfolio CI